Company Focus
Lonza
Latest Lonza News
Biotechnology
German biotech Ethris, a company developing RNA therapeutics and vaccines, and Swiss contract development and manufacturing organization Lonza, have announced a collaboration. 7 April 2025
Cell & Gene Therapy News
Insights
Company Spotlight
A clinical-stage biotech company advancing next generation, potentially curative cell therapies for cancer patients.
Latest News & Features of interest to Lonza
Biotechnology
Shares in Prime Medicine, a US biotech seeking to develop one-time curative genetic therapies, closed 16% lower Monday. 20 May 2025
Biotechnology
Genetic medicines company Arbor Biotechnologies has announced the appointment of Don Haut as chief business officer. 19 May 2025
Biotechnology
The Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report assessing the comparative clinical effectiveness and value of sonpiretigene isteparvovec for the treatment of advanced retinitis pigmentosa. 16 May 2025
Biotechnology
The integration of genomics into the pharmaceutical industry has allowed researchers to better understand the genetic factors underlying diseases, leading to the development of more targeted and effective therapies. 15 May 2025
Pharmaceutical
German science and technology company Merck (MRK: DE) reported a solid start to 2025, with group net sales rising 2.5% organically to 5.3 billion euros ($5.7 billion) in the first quarter. 15 May 2025
Biotechnology
Japanese drugmaker Chugai Pharmaceutical has obtained regulatory approval from the domestic regulator for Elevidys Intravenous Infusion (delandistrogene moxeparvovec) as a regenerative medicine product for the treatment of Duchenne muscular dystrophy (DMD) under the conditional and time-limited approval pathway. 15 May 2025
Biotechnology
Belgian biotech Galapagos is pausing its high-profile plan to break into two separate businesses, just five months after unveiling the ambitious strategy. The company also confirmed a sudden change in leadership, with Henry Gosebruch stepping in as chief executive effective immediately. 14 May 2025
Biotechnology
US regenerative medicine firm Forever Labs has formally spun out SuperShot as a standalone business, a move the company says will allow both entities to sharpen their focus on growth and innovation. 8 May 2025
Pharmaceutical
US pharma major Bristol Myers Squibb is planning a massive $40 billion investment in the country over the next five years. 7 May 2025
Biotechnology
US healthcare giant Johnson & Johnson has presented data from its Phase III LUMEOS study and disclosed that the trial did not meet its primary endpoint. 6 May 2025
Latest In Brief for Lonza
Biotechnology
Kite, a Gilead Sciences company, will share four posters that add to the growing body of evidence to support the clinical use of its chimeric antigen receptor (CAR) T-cell therapy portfolio, at the 7th European CAR T-cell Meeting, 6-8 February 2025, Strasbourg, France. 8 February 2025
Latest Cell & Gene Therapy Ones To Watch News
Belgian biotech Galapagos is pausing its high-profile plan to break into two separate businesses, just five months after unveiling the ambitious strategy. The company also confirmed a sudden change in leadership, with Henry Gosebruch stepping in as chief executive effective immediately. 14 May 2025
17 April 2025
29 March 2025
Cell & Gene Therapy Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze